Vaccine Info

MVA-M1+NP Influenza A

Vaccitech’s MVA-M1+NP vaccine candidate aims to prevent a pandemic and seasonal influenza by eliciting broader and more durable immune protection against all “A strains” of the virus, which cannot be achieved by traditional vaccination. 

The vaccine consists of MVA, a replication-deficient pox viral vector that has been safely tested in thousands of patients, to generate a strong immune reaction against Matrix 1 (M1) and Nucleoprotein (NP) influenza antigens. 

The antigens are highly conserved between influenza A viral subtypes and their intramuscular delivery in Vaccitech’s MVA vector construct induces a potent cell-mediated immune response intended to reduce the likelihood of developing clinical illness from influenza. 

Updated
May 17th, 2019